Hawaii

Yes — compounded semaglutide is available to eligible Hawaii residents through licensed telehealth. It is prepared per-patient by US-licensed compounding pharmacies under FDCA §503A, and a Hawaii-licensed clinician must prescribe it based on a documented, patient-specific clinical rationale. Pallas serves Hawaii with free shipping, typically 3–5 business days after the pharmacy fills your prescription — Honolulu and other Oahu addresses usually ship fastest, with neighbor-island addresses on Maui, Kauai, and the Island of Hawaii sometimes taking a day or two longer. FDA-approved brand-name options like Wegovy^® and Zepbound^® are also available through the same intake.

Start Pallas's online intake, which takes about five minutes and asks about your health history, goals, and current medications. A clinician licensed in Hawaii reviews your intake asynchronously in most cases — no live video visit is required — and, if a GLP-1 is clinically appropriate, sends your prescription to a US-licensed pharmacy. Compounded semaglutide and tirzepatide are prepared per-patient under FDCA §503A based on your documented clinical rationale, and FDA-approved options like Wegovy^® and Zepbound^® are also available through the same intake. Your medication then ships to any Hawaii address — Honolulu, Hilo, or a neighbor island — usually within 3–5 business days.

Several licensed telehealth platforms serve Hawaii residents seeking compounded semaglutide, and the details that matter vary by provider. Before choosing any platform, verify three things — that its clinicians hold an active Hawaii medical or nursing license (an out-of-state license alone is not sufficient), that its compounded medications are prepared by US-licensed 503A pharmacies based on a documented, patient-specific clinical rationale, and that the company is LegitScript Healthcare Merchant Certified, which you can confirm in LegitScript's public certification database. Pallas Health serves Hawaii residents statewide — Honolulu, Maui, Kauai, and the Big Island — connects patients with Hawaii-licensed clinicians, dispenses through US-licensed compounding pharmacies, and is LegitScript Healthcare Merchant Certified.

Start Pallas's online intake and share your health history, goals, and current medications. A Hawaii-licensed clinician reviews your intake asynchronously in most cases — no scheduled video visit required — and, if appropriate, prescribes tirzepatide. Two options are available through the same intake — compounded tirzepatide, prepared per-patient by a US-licensed pharmacy under FDCA §503A based on your documented clinical rationale, and FDA-approved Zepbound^® or Mounjaro^®, offered cash-pay. These are regulated differently, and which one fits you is a clinical decision you make with your provider. Your prescription then ships to any Hawaii address — Honolulu, Hilo, or a neighbor island — usually within 3–5 business days.

No — Hawaii allows asynchronous-first care. Under Hawaii Medical Board guidance, a Hawaii-licensed provider can establish the provider-patient relationship and review your intake by secure message, then prescribe semaglutide or tirzepatide without a scheduled video call, provided the standard of care is met. Your provider may request a video visit or additional information only if your history calls for it.

Pallas is a cash-pay telehealth service — there is no insurance to bill. Your Pallas Membership covers your clinician's review, ongoing check-ins, and care-team messaging; the medication is billed separately and ships free to your Hawaii address, only when a clinician prescribes it. You see your full price during intake before you pay anything — no surprise renewal markups. The price is the same whether you are in Honolulu, Hilo, or a neighbor-island ZIP code. Hawaii Medicaid covers GLP-1s for type 2 diabetes with prior authorization and, in limited cases, weight management, but compounded GLP-1s are not covered — Pallas is cash-pay, so Medicaid rules do not affect your price here.

Eligibility is always decided by a Hawaii-licensed clinician after reviewing your full intake, never by an automated quiz. In general, GLP-1 medications for weight management are considered for adults with a BMI of 30 or higher, or a BMI of 27 or higher together with a weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnea. Your clinician also reviews your medical history and current medications to confirm a GLP-1 is appropriate and safe for you, and will tell you if it is not.

Brand-name medications — Wegovy^® and Ozempic^® (semaglutide) and Zepbound^® and Mounjaro^® (tirzepatide) — are FDA-approved products from their manufacturers, offered cash-pay. Compounded semaglutide and tirzepatide are prepared on a per-patient basis by US-licensed compounding pharmacies, regulated under federal law (FDCA §503A) and by state boards of pharmacy, when a clinician documents a patient-specific clinical need — this is legal when a Hawaii-licensed provider prescribes it for an individual patient and a licensed 503A or 503B pharmacy dispenses it. While these pharmacies are highly regulated, the compounded medications themselves are not FDA-approved, are not generic versions of brand-name drugs, and have not been evaluated by the FDA for safety, efficacy, or quality. Which option fits you is a clinical decision you make with your Hawaii-licensed provider.

Yes, many patients transfer their care to Pallas. During intake you tell your clinician which medication and dose you take now and how you have tolerated it. Your Hawaii-licensed provider reviews that history and, if appropriate, continues you at a comparable dose or adjusts your titration plan. Do not stop or change a prescription on your own — let your clinician guide any transition.

Most patients use a once-weekly injection — sometimes called a GLP-1 shot — with a very fine needle, but a compounded oral semaglutide tablet is available for people who would rather not inject. Both are prescribed only after a clinician confirms they are appropriate for you, and your provider can help you weigh which form fits your routine and goals.

The most common side effects are gastrointestinal — nausea, constipation, diarrhea, or reflux — and they are usually mildest when the dose is raised slowly, which is why clinicians titrate up gradually. GLP-1s are not right for everyone; they are avoided in people with a personal or family history of medullary thyroid carcinoma or MEN2, and during pregnancy. Your Pallas clinician screens for these before prescribing and stays available to help you manage any side effects.

You complete a detailed online intake in under five minutes, sharing your health history, goals, and current medications. A clinician licensed by the Hawaii Medical Board reviews it asynchronously in most cases — no live video required — and may follow up by secure message or request labs if your history calls for it. If a GLP-1 is appropriate, your prescription goes to a licensed pharmacy that ships to any Hawaii address, usually within 3–5 business days.

Pallas care is ongoing, not a one-time script. Your plan renews on a regular cadence so your medication arrives before you run out, and your clinician schedules check-ins to monitor your response, adjust your dose, and manage side effects. You can message your care team, change your plan, or cancel anytime from your patient portal — no phone calls or retention hoops.

Possibly — it depends on your full medication list and health history, so there is no way to answer in the abstract. During intake you list every prescription, over-the-counter medication, and supplement you currently take. Your Hawaii-licensed clinician reviews that list for interactions and contraindications before prescribing, and may follow up with questions about specific medications like insulin, other diabetes drugs, or blood thinners. Never stop or change an existing prescription on your own — let your clinician guide any adjustment.

Most patients start at a low dose so their body can adjust, and your Hawaii-licensed clinician plans a gradual increase over the following weeks based on how you respond. Mild gastrointestinal side effects — nausea, changes in appetite, occasional constipation — are common early on and typically ease as your dose stabilizes. Your care team checks in before any dose change and is reachable by secure message throughout, so you are never guessing whether what you're feeling is expected — even between islands or while traveling.

Yes — independently. Hawaii is a full-practice-authority state, and APRNs granted prescriptive authority by the Hawaii Board of Nursing (HRS § 457-8.6) prescribe medications like semaglutide and tirzepatide with no physician supervision or agreement of any kind. Hawaii permits the clinician-patient relationship to be established through telehealth, and every Pallas prescription follows a clinician's individual review of your full health history — never a questionnaire alone. Every Pallas clinician who treats Hawaii patients holds an active Hawaii license.

Compounded semaglutide injection through Pallas is $139 for your first month, then $597 every 12 weeks ($199/mo average). Cancel anytime. That one plan price includes your US-licensed provider, ongoing check-ins, dose adjustments, and unlimited care-team messaging — no separate membership fee. Medication ships free to any Hawaii address, only if a clinician prescribes it, and you are refunded in full if a clinician decides treatment isn't right for you.

Compounded tirzepatide injection through Pallas is $179 for your first month, then $897 every 12 weeks ($299/mo average). Cancel anytime. That one plan price includes your US-licensed provider, ongoing check-ins, dose adjustments, and unlimited care-team messaging — no separate membership fee. Medication ships free to any Hawaii address, only if a clinician prescribes it, and you are refunded in full if a clinician decides treatment isn't right for you.

Yes. FDA-approved Wegovy^® and Zepbound^® for chronic weight management — plus Ozempic^® and Mounjaro^® for type 2 diabetes — are available to Hawaii patients cash-pay from $1069/mo; insurance is not billed. Whether a brand-name or compounded medication is appropriate for you is determined by a clinician licensed in Hawaii during intake.

That is a decision you make with your clinician. Semaglutide activates the GLP-1 receptor; tirzepatide activates both the GLP-1 and GIP receptors. In the SURMOUNT-5 head-to-head trial of the FDA-approved products, Zepbound^® (tirzepatide 10 mg or 15 mg weekly) produced greater average weight loss than Wegovy^® (semaglutide 1.7 mg or 2.4 mg weekly) — 20.2% versus 13.7% of body weight over 72 weeks. Wegovy^®'s maximum dose is now 7.2 mg weekly, which was not studied in SURMOUNT-5; in the separate STEP UP trial it reached 18.7% average weight loss over 72 weeks. Clinical trial outcomes for the FDA-approved products have not been established for compounded preparations. Individual results vary. Semaglutide plans cost less and semaglutide has the longer post-market record; a clinician licensed in Hawaii weighs your history, goals, and budget to recommend a starting point.